Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-01-14 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - MSB 4 pages 15.3KB
Regulatory Filings Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry or lapse) of certain securities (options) for Mesoblast Limited. It includes specific dates of cessation, number of securities ceased, and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or audit information. It is not a report but a regulatory announcement about securities cessation. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories like share issue or director dealings.
2025-01-14 English
MESOBLAST RAISES NEW CAPITAL FOR RYONCIL COMMERCIAL LAUNCH 2 pages 245.0KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Mesoblast Limited has completed a global private placement raising new capital of A$260 million. The proceeds are intended to fund the commercial launch of a product, clinical development, manufacturing expansion, and working capital. The text includes forward-looking statements and contact information for investors and media. There are no financial statements, detailed financial analysis, or regulatory filings such as 10-K or interim reports. The document is not a report itself but an announcement of a financing event. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7,136 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-01-13 English
Proposed issue of securities - MSB 5 pages 17.2KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement of 104,000,000 ordinary fully paid shares by Mesoblast Limited. It includes specifics about the issue date, pricing, regulatory compliance with ASX Listing Rules, and conditions related to the placement. There is no financial performance data, earnings information, or management discussion. The content is focused on the announcement of a capital raising event through a securities issue. This matches the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the securities issue, not just a brief announcement or reference to a report, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2025-01-13 English
Change in substantial holding 25 pages 1.7MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001 Section 671B, titled 'Notice of change of interests of substantial holder'. It details changes in voting power and relevant interests of JPMorgan Chase & Co. and its affiliates in Mesoblast Ltd. The form includes specifics about share transactions, changes in association, and addresses of entities involved. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of a Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ.
2025-01-09 English
Pause in Trading 1 page 117.1KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It does not contain financial data, report content, or detailed information about financial performance or corporate actions. It is an announcement related to trading status, not a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2025-01-09 English
Trading Halt 2 pages 230.6KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a trading halt requested pending an announcement related to a proposed financing. It references ASX Listing Rule 17.1 and states the halt is until an announcement about financing is made or trading resumes. The document does not contain financial data, detailed financial results, or the actual financing update but is a notice about the trading halt itself. This fits the category of Capital/Financing Update announcements, as it relates to pending financing news and market trading status. The document length is short and it is an announcement, not a full report or detailed presentation. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-01-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.